How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?  

How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers?

If a patient has been on extended duration of 1L treatment and initially had only limited biomarker testing, do you retest full NGS?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice